Treatment of Proteinuria with Lercanidipine Associated with Renin-Angiotensin Axis-Blocking Drugs

Figures & data

Table 1  Blood pressure and analytical changes

	Baseline	One month	Three months	Six months
SBP	152 ± 15	139 ± 1	136 ± 13	135 ± 13
DBP	86 ± 11	81 ± 8	77 ± 8	77 ± 10
HR	74 ± 12	75 ± 12	72 ± 11	71 ± 11
Creatinine	1.69 ± 1.02	1.71 ± 0.94	1.71 ± 1.12	1.69 ± 1.14
Urea	55.2 ± 26.9	64.9 ± 31.0	57.1 ± 29.5	54.2 ± 27.5
Urate	6.4 ± 1.3	6.5 ± 1.2	6.1 ± 1.1	6.3 ± 1.1
Glucose	118 ± 38	112 ± 35	109 ± 37^†	111 ± 30
Cholesterol	210 ± 48	198 ± 47	192 ± 36	192 ± 34^†
Triglycerides	151 ± 77	132 ± 54	130 ± 73	134 ± 72
Total proteins	7.3 ± 0.6	7.4 ± 0.5^†	7.4 ± 0.5^†	7.3 ± 0.6
Serum albumin	4.5 ± 0.7	4.6 ± 0.6	4.5 ± 0.6	4.4 ± 0.6
Clearance	43.5 ± 10.6	44.1 ± 12.5	43.9 ± 11.2	44.0 ± 1.0
Proteinuria	1.63 ± 1.39	1.16 ± 1.16	1.00 ± 1.04	1.09 ± 1.26

Blood pressure in mmHg. HR as bpm. Creatinine, urea, urate, glucose, cholesterol, and triglycerides in mg/dL. Total proteins and serum albumin in g/dL. Creatinine clearance as mL/min. Proteinuria in expressed as g/24h.

*p < 0.001 vs. baseline; ^†p < 0.05 vs. baseline; ^‡p = 0.001.

Figure 1.  SBP and DBP were significantly reduced in all visits.

Figure 2.  A significant decrease of proteinuria (expressed as percentage from baseline) was seen at the second visit; it was deeper at three months and remains until the end of follow-up. Comparative reduction of blood pressure was very less deep.